JP2012522989A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522989A5
JP2012522989A5 JP2012503660A JP2012503660A JP2012522989A5 JP 2012522989 A5 JP2012522989 A5 JP 2012522989A5 JP 2012503660 A JP2012503660 A JP 2012503660A JP 2012503660 A JP2012503660 A JP 2012503660A JP 2012522989 A5 JP2012522989 A5 JP 2012522989A5
Authority
JP
Japan
Prior art keywords
biomarkers
subject
level
acid
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012503660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/029399 external-priority patent/WO2010114897A1/en
Publication of JP2012522989A publication Critical patent/JP2012522989A/ja
Publication of JP2012522989A5 publication Critical patent/JP2012522989A5/ja
Pending legal-status Critical Current

Links

JP2012503660A 2009-03-31 2010-03-31 インスリン抵抗性に関連するバイオマーカー、及びそれを使用する方法 Pending JP2012522989A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16533609P 2009-03-31 2009-03-31
US61/165,336 2009-03-31
US16657209P 2009-04-03 2009-04-03
US61/166,572 2009-04-03
PCT/US2010/029399 WO2010114897A1 (en) 2009-03-31 2010-03-31 Biomarkers related to insulin resistance and methods using the same

Publications (2)

Publication Number Publication Date
JP2012522989A JP2012522989A (ja) 2012-09-27
JP2012522989A5 true JP2012522989A5 (https=) 2013-01-17

Family

ID=42828685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012503660A Pending JP2012522989A (ja) 2009-03-31 2010-03-31 インスリン抵抗性に関連するバイオマーカー、及びそれを使用する方法

Country Status (6)

Country Link
US (1) US20120122981A1 (https=)
EP (1) EP2414535A4 (https=)
JP (1) JP2012522989A (https=)
CN (1) CN102449161A (https=)
BR (1) BRPI1013387A2 (https=)
WO (1) WO2010114897A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009001862A1 (ja) * 2007-06-25 2010-08-26 味の素株式会社 内臓脂肪蓄積の評価方法
MX2010000414A (es) * 2007-07-17 2010-04-01 Metabolon Inc Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos.
US10215765B2 (en) 2010-09-15 2019-02-26 Quest Diagnostics Investments Incorporated Detection of vitamins A and E by tandem mass spectrometry
WO2012058298A1 (en) * 2010-10-26 2012-05-03 Mayo Foundation For Medical Education And Research Biomarkers of reduced insulin action
KR101303825B1 (ko) * 2011-06-02 2013-09-05 연세대학교 산학협력단 혈장 대사체를 이용한 제2형 당뇨병 진단 키트
WO2013002381A1 (ja) 2011-06-30 2013-01-03 味の素株式会社 脂肪性肝疾患の評価方法、脂肪性肝疾患評価装置、脂肪性肝疾患評価方法、脂肪性肝疾患評価プログラム、脂肪性肝疾患評価システム、情報通信端末装置、および脂肪性肝疾患の予防・改善物質の探索方法
US10302663B2 (en) 2011-09-14 2019-05-28 Metabolon, Inc. Method of assessing pancreatic beta-cell function
EP2642293A1 (en) 2012-03-22 2013-09-25 Nestec S.A. 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing
EP2642295A1 (en) * 2012-03-22 2013-09-25 Nestec S.A. 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9361429B2 (en) * 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9546994B2 (en) 2012-08-13 2017-01-17 Helmholtz Zentrum Munchen-Deutsches Forschungszentrum fur Geseundheit und Umwelt (GmbH) Biomarkers for type 2 diabetes
US20140324460A1 (en) * 2012-09-26 2014-10-30 Health Diagnostic Laboratory, Inc. Method for determining and managing total cardiodiabetes risk
CA2896539C (en) * 2012-12-26 2018-07-03 Quest Diagnostics Investments Incorporated C peptide detection by mass spectrometry
WO2014110525A1 (en) * 2013-01-11 2014-07-17 Health Diagnostic Laboratory, Inc. Method of detection of clinically significant post-prandial hyperglycemia in normoglycemic patients
WO2014120449A1 (en) * 2013-01-31 2014-08-07 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
US20140278121A1 (en) * 2013-03-13 2014-09-18 Robust for Life, Inc. Systems and methods for network-based calculation and reporting of metabolic risk
EP3041402A4 (en) * 2013-09-04 2017-08-23 Joseph Michael Lawless Kelly Methods and systems for the detection of disease
JP2017516085A (ja) * 2014-04-08 2017-06-15 メタボルン インコーポレーティッド 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法
JP6051258B2 (ja) * 2015-04-15 2016-12-27 ライオン株式会社 脂質異常症への罹患しやすさを試験する方法
JP6051257B2 (ja) * 2015-04-15 2016-12-27 ライオン株式会社 脂質異常症への罹患しやすさを試験する方法
JP6873490B2 (ja) * 2015-10-18 2021-05-19 ジア,ウェイ 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置
GB201522302D0 (en) * 2015-12-17 2016-02-03 Mars Inc Food product for regulating lipid metabolites
CN106093430A (zh) * 2016-06-06 2016-11-09 上海阿趣生物科技有限公司 可用于检测糖尿病的标志物及其用途
CN107022018B (zh) * 2016-08-16 2018-04-13 北京毅新博创生物科技有限公司 检测胰岛素抵抗的组合物及产品和用途
CN106442770B (zh) * 2016-09-05 2019-01-18 南京医科大学 与特发性男性不育相关的精浆代谢小分子标志物及其检测方法和应用
CN106908605B (zh) * 2017-01-22 2019-02-22 中国人民解放军军事医学科学院基础医学研究所 eLtaS蛋白作为预防和治疗胰岛素抵抗相关疾病的药物靶点的应用
EP3901631A3 (en) * 2017-08-17 2021-12-29 Société des Produits Nestlé S.A. Markers in prepuberty for childhood-prediabetes
CN108623655B (zh) * 2018-05-15 2020-09-01 浙江省农业科学院 改善胰岛素抵抗的二肽el及其用途
CN109298084A (zh) * 2018-07-23 2019-02-01 上海市东方医院 用于检测血清或者血浆中油酸浓度的试剂盒及其制备方法和应用
EP3857232A1 (en) * 2018-09-27 2021-08-04 Société des Produits Nestlé S.A. Markers of risk to develop insulin resistance during childhood and young adulthood
CN110887808A (zh) * 2019-10-28 2020-03-17 广东省测试分析研究所(中国广州分析测试中心) 一种红外光谱技术快速检测阿卡波糖发酵过程中的糖源含量的方法
CN112903885B (zh) * 2019-12-03 2022-05-06 中国科学院大连化学物理研究所 一种筛查糖尿病的联合型代谢标志物的应用及其试剂盒
CN213980949U (zh) 2020-08-27 2021-08-17 康明斯电力公司 用于发电机组的系统
CN112461986B (zh) * 2021-02-03 2021-06-08 首都医科大学附属北京友谊医院 一种用于评估空腹血糖受损和2型糖尿病患病风险的整合生物标志物体系
EP3922990B1 (en) 2021-03-28 2024-05-08 MS Ekspert Sp. z o.o. System for automatic changing and sealing of disposable chromatographic columns in high-performance liquid chromatography; measurement method and its application in the analysis of biomarker of rare disease
CN113929762B (zh) * 2021-12-16 2022-04-26 清华大学 3-羟基丁酰化和/或3-羟基戊酰化修饰胰岛素及其应用
CN117159717A (zh) * 2023-09-28 2023-12-05 广东省人民医院 Slc25a33在制备预防或治疗葡萄糖代谢相关疾病的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031103A1 (en) * 1996-02-20 1997-08-28 Kyowa Hakko Kogyo Co., Ltd. Method for determining 1,5-anhydroglucitol
WO2002098355A2 (en) * 2001-06-01 2002-12-12 Clingenix, Inc. Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
EP2126589A4 (en) * 2007-02-22 2011-06-08 Lipomics Technologies Inc METABOLISM AND DIABETIC SUFFERING AND METHOD OF USE THEREOF
MX2010000414A (es) * 2007-07-17 2010-04-01 Metabolon Inc Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos.

Similar Documents

Publication Publication Date Title
JP2012522989A5 (https=)
JP2015064362A5 (https=)
Kang et al. Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis
JP6927212B2 (ja) 軽度認知障害又はアルツハイマー型認知症の評価方法
Lehmann et al. Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver
Noto et al. Metabolomics in newborns
JP2010537157A5 (https=)
JP6870679B2 (ja) アルツハイマー型認知症の将来の発症リスクの評価方法
JP2016520192A5 (https=)
JP2016509222A (ja) インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法
Zhang et al. Machine learning applied to serum and cerebrospinal fluid metabolomes revealed altered arginine metabolism in neonatal sepsis with meningoencephalitis
JP7123329B2 (ja) 腎臓病の予後予測方法及びシステム
Liu et al. Dynamic proteomic analysis of protein expression profiles in whole brain of Balb/C mice subjected to unpredictable chronic mild stress: implications for depressive disorders and future therapies
Sylvestre et al. Untargeted metabolomic analysis of plasma from relapsing-remitting multiple sclerosis patients reveals changes in metabolites associated with structural changes in brain
JP2012521551A5 (https=)
ES2749048T3 (es) Biomarcadores para evaluar el VIH
Yang et al. Metabolomics in viral hepatitis: advances and review
CN103837620A (zh) 一种同时检测人体血浆中多种氨基酸含量的方法
JP6762529B2 (ja) 腎臓病の病態バイオマーカー
Han et al. Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with Type 1 diabetes
Bratt et al. Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin
WO2015030211A1 (ja) 疲労のバイオマーカーおよびその利用
Liu et al. The interaction of ammonia and manganese in abnormal metabolism of minimal hepatic encephalopathy: a comparison metabolomics study
Wang et al. The role of metabolomics in stroke: biomarkers of diagnosis and therapy
Kartsova et al. Application of chromatographic and electrophoretic techniques to metabolomic studies